Analysis Survival of Breast Cancer with Brain Metastases Treated with Different Fraction Whole Brain Radiotherapy Concomitant with Capecitabine
DOI:
https://doi.org/10.3889/oamjms.2021.6360Keywords:
Whole brain radiotherapy, Capecitabine, Breast cancer, Brain metastasesAbstract
Introduction: Breast cancer is the second most frequent cancer worldwide. The main therapeutic modality for breast cancer with brain metastases is radiation. Whole Brain Radiotherapy (WBRT) is a treatment that provides moderate doses of radiotherapy to all brain tissue. Capecitabine was found to be effective for the treatment of breast cancer with metastases and its metabolites can cross the BBB in animal models.
Objective: This study aims to determine the response and survival of breast cancer patient with brain metastases treated with different fractionation WBRT combined with capecitabine administration.
Materials and methods: This is a prospective, randomized-blind cohort analytic study. Subjects were randomized into two groups by giving different fraction of WBRT (Group I WBRT 10x3Gy and Group II WBRT 20x2Gy) concomitant with capecitabine 850-1000mg/m2. OS was calculated from brain metastases diagnosis. Median follow-up was 5.6 months.
Results: A total of 22 breast cancer patients with brain metastases participated in this study. Group I obtained results of 5 (45.5%) out of 11 are responding to therapy and median OS was 4.4 months. Whereas in group II found 11 (100%) out of 11 patients responded to therapy and median OS was 9.4 months. The results of statistical analysis showed that there were significant differences of response between the two groups with p value= 0.012. The differences of survival of each group also statistically significant with p value=0.004
Conclusions: WBRT with 20x2Gy concomitant with Capecitabine gives a better response rate and OS.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
American Cancer Society. Cancer Treatment and Survivorship Facts and Figures. United States: American Cancer Society; 2014.
Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, et al. Breast Cancer metastasis: Challenges and opportunities. Cancer Res. 2009;69(12):4951-3. https://doi.org/10.1158/0008-5472.can-09-0099 PMid:19470768 DOI: https://doi.org/10.1158/0008-5472.CAN-09-0099
Devita VT, Lawrence TS, Rosenberg SA. Brain metastasis. In: Cancer Principles and Practice of Oncology. 9th ed. Netherlands: Wolters Kluwer India Pvt. Ltd.; 2011.
Patchell R, Regine W. Brain metastase: Whole brain radiation therapy perspective. In: Principles and Practice of Stereotactic Radiosurgery. Berlin, Germany: Springer; 2008. p. 201-5. https://doi.org/10.1007/978-0-387-71070-9_16 DOI: https://doi.org/10.1007/978-0-387-71070-9_16
Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer. 2006;107(6):1348-54. https://doi.org/10.1002/cncr.22127 PMid:16909414 DOI: https://doi.org/10.1002/cncr.22127
McEvoy G. Capecitabine. In: AHFS Drug Information. Bethesda, MD: American Society of Health-system Pharmacists; 2002. p. 916-21.
Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int J Radiat Oncol. 1997;37(4):745-51. https://doi.org/10.1016/s0360-3016(96)00619-0 PMid:9128946 DOI: https://doi.org/10.1016/S0360-3016(96)00619-0
Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm-general principles. Nat Clin Pract Oncol. 2007;4(2):86-100. https://doi.org/10.1038/ncponc0714 PMid:17259930 DOI: https://doi.org/10.1038/ncponc0714
Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res. 1999;5(10):2948-53. PMid:10537364
Wang ML, Yung WK, Royce ME, Schomer DF, Theriault RL. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol. 2001;24(4):421-4. https://doi.org/10.1097/00000421-200108000-00026 PMid:11474279 DOI: https://doi.org/10.1097/00000421-200108000-00026
Fabi A, Vidiri A, Ferretti G, Felici A, Papaldo P, Carlini P, et al. Dramatic regression of multiple brain metastases from breast cancer with capecitabine: Another arrow at the bow? Cancer Invest. 2006;24(4):466-8. https://doi.org/10.1080/07357900600705805 PMid:16777702 DOI: https://doi.org/10.1080/07357900600705805
Ekenel M, Hormigo AM, Peak S, DeAngelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol. 2007;85(2):223-7. https://doi.org/10.1007/s11060-007-9409-0 PMid:17611719 DOI: https://doi.org/10.1007/s11060-007-9409-0
Chargari C, Kirova YM, Diéras V, Pena PC, Campana F, Cottu PH, et al. Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients. J Neurooncol. 2009;93(3):379-84. https://doi.org/10.1007/s11060-008-9791-2 PMid:19169856 DOI: https://doi.org/10.1007/s11060-008-9791-2
Noordijk EM, Vecht CJ, Haaxma-Reiche H, Padberg GW, Voormolen JH, Hoekstra FH, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol. 1994;29(4):711-7. https://doi.org/10.1016/0360-3016(92)90169-i PMid:8040016 DOI: https://doi.org/10.1016/0360-3016(92)90169-I
Downloads
Published
How to Cite
License
Copyright (c) 2020 Rudiyo Yeoh, Iskandar Japardi, Aznan Lelo, R. Susworo, Jacub Pandelaki, Adang Bachtiar, Suzy Indharty, Hendriyo Yeoh, Juli Jamnasi, William Omar, Sudibio Sudibio (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
